Home
Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

Today’s Highlights May 24, 2019

Amgen, the Biotech King
Amgen (AMGN), the biotech king, wanted to buy all of the Denmark biotech firm Nuevolution's drug discovery platform. This platform attracted Amgen in 2016 as well as many other large pharma firms including: Merck, Johnson and Johnson, GlaxoSmithKline and Novartis.

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
, ,
May 24, 2019

Other Articles